Independent predictors associated with GLP-1 RA use were age <75 years, having HFrEF and a longer duration of T2DM, obesity, registration in SwedeHF after release of the 2019 European Society of Cardiology/European Association for the Study of Diabetes (ESC/EASD) guidelines, heart rate >70 b.p.m., glycated haemoglobin A1c (HbA1c) >53 mmol/mol, lower low-density lipoprotein cholesterol levels and NT-proBNP, university education, concomitant use of SGLT2i or other antidiabetic medications, and an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 (Figure 1). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.